Table 5. Summary of previous reports on EGFR gene mutations in NSCLC.
| Reference | Patient group | No. of patients |
Frequency in
|
Predilection in non/former smokers | Histological features in Ada | Respose to TKIbof patients with EGFR mutated tumour | Correlation to p53 | Correlation to K-ras | |
|---|---|---|---|---|---|---|---|---|---|
| Overall | Ada | ||||||||
| Lynch et al (2004) | USA | 25 +16 TKIb receivers | 2/25 | 2/22 | Yes | More frequent in BACc | 8 patients in 9 responders not in 7 nonresponders | — | — |
| Paez et al (2004) | USA Japan | 119 +9 TKIb receivers | 16/119 (13%) 1/61(2%) in USA 15/58 (26%) in Japan | 15/70 (21%) 1/29(3%) in USA 14/41(34%) in Japan | Yes | — | 5 patients in 5 responders not in nonresponders | — | — |
| Pao et al (2004) | USA | 96 +17 TKI b responders | 11/96 (11%) | — | Yes | — | 12 patients in 17 responders | — | — |
| Kosaka et al (2004) | Japan | 277 | 111/277 (40%) | 110/224 (49%) | Yes | More frequent in well-to-mederately differentiated Ada | — | Independent | Mutually exclusive |
| Huang et al (2004) | Taiwan | 101 | 39/101 (39%) | 38/69 (55%) | Yes | — | 7 responders in 9 patients | — | — |
| Marchetti et al (2005) | Italy | 860 | 37/860 (4%) | 37/375 (10%) | Yes | More frequent in Ad with BACc features | — | — | Mutually exclusive |
| Han et al (2005) | Korea | 90 | 17/90 (19%) | 14/65 (22%) | No | — | 11 responders in 17 patients | — | — |
| Shigematsu et al (2005) | Japan Taiwan USA Australia | 519 | 120/519 (23%) 107/361 (30%) in East Asia 13/158(8%) in others | 114/289 (39%) 102/214 (48%) in East Asia 12/75(16%) in others | Yes | No correlation to Ad with BACc fearures | — | — | Mutually exclusive |
| Qin et al (2005) | China | 41 | 10/41 (24%) | 7/17 (41%) | No | — | — | — | — |
| Yang et al (2002) | USA | 219 | 26/219 (12%) | 25/164 (15%) | Yes | — | — | — | — |
a
Ad=adenocarcinoma.
b
TKI=tyrosine kinase inhibitor.
c
BAC=bronchio-alveolar carcinoma.